Key points from article :
CuraSen Therapeutics is set to initiate its first-in-human clinical trial for CST-3056, a new drug targeting Alzheimer’s disease and related cognitive impairments, in Q4 2024. The company recently secured $5.8 million in funding from the Alzheimer’s Drug Discovery Foundation to support nonclinical safety studies and the upcoming Phase I trial. CST-3056 is an alpha-1A adrenoceptor agonist designed to address neurodegenerative diseases by impacting brain function.
The Phase I trial will evaluate the safety and pharmacokinetics of CST-3056, initially enrolling healthy volunteers, with the final cohort including Alzheimer’s patients or individuals with mild cognitive impairment (MCI). The study aims to ensure the drug is as safe and well-tolerated in the target population as it is in healthy subjects. Additionally, the trial will incorporate tests to measure brain activity and cognitive function, assessing whether the drug has a beneficial impact on brain health.
Alongside this, CuraSen plans a Phase II trial for its Parkinson's disease drug, CuraCN, which combines clenbuterol and nadolol. Scheduled for mid-2024, this trial will test the drug’s effects on cognitive function, memory, and mood in patients with significant non-motor symptoms of Parkinson’s. A follow-up Phase II dose-selection study is planned, with both trials expected to be completed by 2026.
